T2DMis today considered as world-wide health problem, with complications responsible of an enhanced mortality and morbidity.Thus, new strategies for its prevention and therapy are necessary. For this reason, the research interest has focused its attentionon TLR4 and its polymorphisms, particularly the rs4986790. However, no conclusive findings have been reported until now aboutthe role of this polymorphism in development of T2DM and its complications, even if a recent meta-analysis showed its T2DMassociation in Caucasians. In this study, we sought to evaluate the weight of rs4986790 polymorphism in the risk of the majorT2DMcomplications, including 367 T2DMpatients complicated for the 55.6%. Patients with A/A and A/G TLR4 genotypes showedsignificant differences in complication’s prevalence. In particular, AG carriers had higher risk prevalence for neuropathy (P =0.026), lower limb arteriopathy (P = 0.013), and the major cardiovascular pathologies (P = 0.017). Their cumulative risk wassignificant (P = 0.01), with a threefold risk to develop neuropathy, lower limb arteriopathy, and major cardiovascular events in AGcases compared to AA cases.The adjusted OR for the confounding variables was 3.788 (95% CI: 1.642–8.741).Thus, the rs4986790polymorphism may be an indicative of prevalence of complications in T2DM patients.
|Numero di pagine||8|
|Rivista||Mediators of Inflammation|
|Stato di pubblicazione||Published - 2014|